pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

9,396 catalysts · 3,603 8k filing · 1,776 grant · 1,000 device adverse event · 852 approval · 642 device 510k · 585 earnings

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2026-02-03×clear all
type
  • 8k filing3,603
  • grant1,776
  • device adverse event1,000
  • approval852
  • device 510k642
  • earnings585
  • device pma493
  • device recall198
  • phase 2 completion172
  • recall167
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    50
    ›Apr 22, 2026drug shortage130d agoDextrose Monohydrate 50% Injection shortage — Hospira, Inc., a Pfizer Company

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoHeparin Sodium Injection shortage — Hospira, Inc., a Pfizer CompanyPharmacia & Upjohn LLC

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoMorphine Sulfate Injection shortage — Hospira, Inc., a Pfizer CompanyTeva Pharmaceuticals USA Inc

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoSodium Acetate Injection shortage — Hospira, Inc., a Pfizer CompanyAmneal Pharmaceuticals, Inc.

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoPalbociclib Capsule shortage — Pfizer Inc.PFIZER INC

    Status: To Be Discontinued. Reason: not specified. Form: Capsule

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoClindamycin Phosphate Injection shortage — Pfizer Inc.PFIZER INC

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoCarboplatin Injection shortage — Hospira, Inc., a Pfizer CompanyOncotelic Therapeutics, Inc.

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoEtomidate Injection shortage — Hospira, Inc., a Pfizer CompanyCaplin Steriles Ltd

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoDobutamine Hydrochloride Injection shortage — Hospira, Inc., a Pfizer CompanySlate Run Pharmaceuticals LLC

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›Apr 22, 2026drug shortage130d agoSufentanil Citrate Injection shortage — Hospira, Inc., a Pfizer CompanyTALPHERA, INC.

    Status: Current. Reason: not specified. Form: Injection

    full page →fda drug shortages ↗
    ›04/23/2026recall129d agoFrederik’s by Meijer recall: Food & Beverages, Allergens

    Vanilla Bourbon Trail Mix

    full page →fda recalls ↗
    ›Apr 23, 20268k filing129d ago$MBRX — Moleculin Biotech, Inc. (MBRX) — 8-K filingMoleculin Biotech, Inc.

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$TECX — Tectonic Therapeutic, Inc. (TECX) — 8-K filingTectonic Therapeutic, Inc.

    Items: 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$NKTR — NEKTAR THERAPEUTICS (NKTR) — 8-K filingNEKTAR THERAPEUTICS

    Items: 1.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$TNXP — Tonix Pharmaceuticals Holding Corp. (TNXP) — 8-K filingTonix Pharmaceuticals Holding Corp.

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$ZURA — Zura Bio Ltd (ZURA) — 8-K filingZura Bio Ltd

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$INDP — Indaptus Therapeutics, Inc. (INDP) — 8-K filingIndaptus Therapeutics, Inc.

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d agoSemnur Pharmaceuticals, Inc. (SMNR, SMNRW) — 8-K filingSemnur Pharmaceuticals, Inc.

    Items: 1.02

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$BMRN — BIOMARIN PHARMACEUTICAL INC (BMRN) — 8-K filingBIOMARIN PHARMACEUTICAL INC

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$FOLD — AMICUS THERAPEUTICS, INC. (FOLD) — 8-K filingAMICUS THERAPEUTICS, INC.

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$WST — WEST PHARMACEUTICAL SERVICES INC (WST) — 8-K filingWEST PHARMACEUTICAL SERVICES INC

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$CRVS — Corvus Pharmaceuticals, Inc. (CRVS) — 8-K filingCorvus Pharmaceuticals, Inc.

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$IQV — IQVIA HOLDINGS INC. (IQV) — 8-K filingIQVIA HOLDINGS INC.

    Items: 5.02, 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$CNTB — Connect Biopharma Holdings Ltd (CNTB) — 8-K filingConnect Biopharma Holdings Ltd

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$BBOT — BridgeBio Oncology Therapeutics, Inc. (BBOT) — 8-K filingBridgeBio Oncology Therapeutics, Inc.

    Items: 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$UTMD — UTAH MEDICAL PRODUCTS INC (UTMD) — 8-K filingUTAH MEDICAL PRODUCTS INC

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$ANGO — ANGIODYNAMICS INC (ANGO) — 8-K filingANGIODYNAMICS INC

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$SGHT — Sight Sciences, Inc. (SGHT) — 8-K filingSight Sciences, Inc.

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$CPIX — CUMBERLAND PHARMACEUTICALS INC (CPIX) — 8-K filingCUMBERLAND PHARMACEUTICALS INC

    Items: 1.01, 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$VXRT — Vaxart, Inc. (VXRT) — 8-K filingVaxart, Inc.

    Items: 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$SSII — SS Innovations International, Inc. (SSII) — 8-K filingSS Innovations International, Inc.

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 23, 20268k filing129d ago$DAWN — Day One Biopharmaceuticals, Inc. (DAWN) — 8-K filingDay One Biopharmaceuticals, Inc.

    Items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 2026patent expiry128d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026patent expiry128d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026drug expiry128d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry128d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026phase 1 completion128d agoLarkspur Biosciences Inc — undisclosed drug (Phase I Trial Completion)undisclosed drug

    Therapy area: Undisclosed. Indication: Unspecified

    full page →undisclosed drug →source: globaldata
    ›Apr 24, 2026phase 1 completion128d agoAkeso Inc — AK-132 (Phase I Trial Completion)AK-132

    Therapy area: Oncology. Indication: Solid Tumor

    full page →AK-132 →source: globaldata
    ›Apr 24, 2026phase 1 initiation128d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

    Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

    full page →CMSD-001 →source: globaldata
    ›Apr 24, 2026phase 1 results128d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

    Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

    full page →viral-specific T-cells →source: globaldata
    ›Apr 24, 2026phase 1 results128d agoMedicus Pharma Ltd — teverelix (Phase I Trial Results)teverelix

    Therapy area: Women's Health. Indication: Endometriosis

    full page →teverelix →source: globaldata
    ›Apr 24, 2026phase 1 results128d agoMedicus Pharma Ltd — teverelix (Phase I Trial Results)teverelix

    Therapy area: Women's Health. Indication: Endometriosis

    full page →teverelix →source: globaldata
    ›Apr 24, 2026phase 1 2 completion128d agoSt. Paul's Hospital — methoxyflurane (Phase I/II Trial Completion)methoxyflurane

    Therapy area: Central Nervous System, Ear Nose Throat Disorders. Indication: Pain, Rhinosinusitis

    full page →methoxyflurane →source: globaldata
    ›Apr 24, 2026phase 1 2 completion128d agoUniversity of Otago — ketamine (Phase I/II Trial Completion)ketamine

    Therapy area: Central Nervous System. Indication: Anxiety Disorders, Post-Traumatic Stress Disorder (PTSD)

    full page →ketamine →source: globaldata
    ›Apr 24, 2026phase 1 2 initiation128d agoMayo Clinic — eflornithine hydrochloride (Phase I/II Trial Initiation)eflornithine hydrochloride

    Therapy area: Oncology. Indication: Anaplastic Astrocytoma, Glioblastoma Multiforme (GBM), High-Grade Glioma, Low-Grade Astrocytoma, Malignant Glioma, Oligodendroglioma

    full page →eflornithine hydrochloride →source: globaldata
    ›Apr 24, 2026phase 2 completion128d agoUniversity Health Network — bevacizumab (Phase II Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

    full page →bevacizumab →source: globaldata
    ›Apr 24, 2026phase 2 completion128d agoXijing Hospital — propofol (Phase II Trial Completion)PROPOFOL

    Therapy area: Central Nervous System. Indication: Delirium

    full page →PROPOFOL →source: globaldata
    ›Apr 24, 2026phase 2 completion128d agoKothiwal Dental College and Research Centre — platelet rich plasma (Phase II Trial Completion)platelet rich plasma

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →platelet rich plasma →source: globaldata
    ›Apr 24, 2026phase 2 completion128d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

    Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

    full page →lixudebart →source: globaldata
    ›Apr 24, 2026phase 2 completion128d agoSwinburne University of Technology — dronabinol (Phase II Trial Completion)dronabinol

    Therapy area: Central Nervous System. Indication: Anxiety Disorders, Insomnia, Pain

    full page →dronabinol →source: globaldata
    ← prev
    page 106 of 188
    next →
    $MBRX2.1000-2.33%
    $TECX29.56+1.34%
    $NKTR72.52-2.72%
    $AMRX17.54-2.61%
    $OTLC0.0373-8.80%
    $PFE27.96-0.21%
    $ZURA5.6400-0.88%
    $TNXP13.56-0.59%
    $TLPH1.2000-2.44%
    $PFE27.96-0.21%
    $INDP2.7700+4.73%
    $IQV198.52-1.54%
    $SMNRW0.09000.00%
    $CRVS14.16-3.80%
    $UTMD69.19+0.06%
    $FOLD14.490.00%
    $BMRN64.67-0.96%
    $CNTB2.2000-0.45%
    $BBOT9.1800-0.86%
    $WST358.41-0.23%
    $ANGO13.82-2.81%
    $SGHT5.0300+2.44%
    $CPIX8.4600-2.20%
    $VXRT0.5083+1.66%
    $MDCX0.3842+2.59%
    $DAWN21.530.00%
    $SSII3.58000.00%
    $MDCX0.3842+2.59%